Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire

Aug.08.2022
Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire
The Philippines' proposed e-cigarette law facing opposition from health officials and advocates for public health.

On his first day in office, Philippine President Marcos vetoed the bill to establish the special ecological zone at the Bura-gan airport city, sending a message that public interest should prevail over commercial profits.


However, the proposed Nicotine and Non-Nicotine Aerosol Products Regulation Act appears to be anything but. The President allowed the act to lapse on July 25th. While the e-cigarette bill would expand its market base and bring more funding to the tobacco industry, it is seen as harmful to health because it would allow individuals as young as 18 to buy, use, and sell e-cigarettes and heated tobacco products, and would lift flavor restrictions on e-cigarette liquids.


The National Health, Food and Drug Administration, Ministry of Education, Ministry of Finance, as well as dozens of medical associations and former health ministers, are strongly lobbying against an electronic cigarette bill. They believe that this puts the country's youth at risk of harmful effects from electronic cigarettes. Former health minister Francisco Duque opposed the claim that electronic cigarettes can help people quit smoking. He said that they typically have the opposite effect as they lead people to engage in more bad habits such as drinking and illegal drug use.


The Philippines is one of the countries with the highest smoking rates among adults and youth around the world. The Global Adult Tobacco Survey in 2015 revealed that nearly 23.8% of Filipino adults used some form of tobacco, with 22.7% of the population being smokers and 18.7% of them being daily smokers.


Approximately 117,000 people die each year in the country due to tobacco-related illnesses such as lung cancer and cardiovascular disease. The cost of treating the four main diseases caused by tobacco use in the Philippines is estimated to be 46.4 billion pesos.


Child rights activists and tobacco control advocates believe that the e-cigarette bill is a "victory for tobacco capital.


The public interest law organization, ImagineLaw, has stated that allowing this bill to become law would be a "betrayal of public health" and a "regrettable development" in light of President Marcos' promise to rebuild the country better.


When the President does not take action after receiving a legislative measure for 30 days, the legislation expires. The previous Congress shelved the e-cigarette bill for five months and on June 24th forwarded a registered copy to Malacañang, just six days before then-President Rodrigo Duterte's term ended.


Health experts and tobacco control advocates are calling for the rejection of the proposed bill, as its provisions conflict with public health goals and international standards, particularly in light of the Supreme Court's ruling in late June upholding the FDA's jurisdiction over tobacco products and reaffirming the country's commitment to the World Health Organization's Framework Convention on Tobacco Control.


Marcos hails from the Ilocos region where tobacco is the main cash crop. Allowing the electronic cigarette bill to expire puts narrow interests ahead of the common good.


Some are calling for the immediate convening of the Legislative-Executive Development Advisory Council (LEDAC) by the President and have pointed out that while the veto power is within the President's rights, its frequent use may strain relations between the executive and legislative branches of government.


In the coming days when meeting with congressional leaders, it should be clear that they will prioritize legislation that serves the public interest, rather than industry profits. The public interest should never be relegated to a secondary position.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning only.


This article does not represent the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the article's content. The compilation of this article is only intended for communication and research within the industry.


Due to limitations in the compiler's ability, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain's cigarette volumes declined 5.2% year over year in August 2026, according to government data cited by UBS and reported by Investing.com on October 7. British American Tobacco's volumes fell 14.5%, followed by Imperial Brands at 8.8%, Philip Morris International at 6.6% and Japan Tobacco at 4.6%. JTI was the only one of the four companies to gain cigarette market share, rising six basis points to 26.7%. In France, official customs data showed an unadjusted 3.7% decline in cigarette deliveries. Adjusting for the difference in delivery days produces a decline of approximately 8.3%, consistent with the UBS figure. The bank also estimated the earnings exposure of major tobacco companies to both markets.
Market
Oct.13
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Vaping brand OXVA introduced the XLIM PRO 4 refillable pod system in October 2026, featuring Anti-Burn Tech (ABT) based on smart e-liquid-level detection. The system can issue refill alerts and stop power output when e-liquid levels become too low. ABT requires the XLIM PRO 4 device and a dedicated XLIM ABT cartridge. Standard XLIM pods remain compatible but do not support ABT protection. OXVA previously introduced temperature-based anti-burn technology in the XLIM Pro 2 DNA, developed with Evolv. The new device features a 1,800mAh battery, 5–30W output and a 0.98-inch HD color screen. OXVA's official store lists the device at $37.90 and dedicated ABT replacement cartridges at $12.99. Independent testing confirmed the low-liquid protection response but recorded varying cartridge lifespans.
product
Oct.30
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23